摘要
目的:评价富马酸替诺福韦二吡呋酯片抗乙型肝炎病毒(HBV)应答与慢性乙型肝炎(CHB)患者体内血药谷浓度、HBeAg水平变化的相关性。方法:收集医院2017年—2019年收治的接受富马酸替诺福韦二吡呋酯片(300 mg/d)单药抗HBV治疗的慢性乙型肝炎患者46例病历资料,根据纳入标准和HBeAg水平将其分为阴性组(≤1.0 U/mL)、低水平组(>1.0~50.0 U/mL)、中水平组(>50.0~1000.0 U/mL)和高水平组(>1000.0 U/mL);分析与评价患者经富马酸替诺福韦二吡呋酯片治疗后抗HBV应答与血药谷浓度、HBeAg水平三者之间的相关性。结果:治疗后经Pearson相关性分析结果显示,患者HB V-DNA达标速度与血药谷浓度呈正相关(P<0.01),而与HBeAg水平呈单侧负相关(P_(0.028)<0.05),而与入组患者性别(P_(0.793)>0.05)、年龄(P_(0.894)>0.05)则无相关性。结论:富马酸替诺福韦二吡呋酯片抗HBV应答与慢性乙肝患者血药谷浓度水平呈正相关。
Objective:To evaluate the correlation between the anti-hepatitis B virus(HBV)response of tenofovir disoproxil fumarate(TDF)tablets with the changes of serum valley concentration and HBeAg level in patients with chronic hepatitis B(CHB).Methods:The medical records of 46 patients with chronic hepatitis B who received TDF tablets(300 mg/d)from 2017 to 2019 were collected.Based on inclusion criteria and HBeAg level,they were divided into negative group(less than or equal to 1.0 U/mL),low level group(greater than between 1.0 and 50.0 U/mL),medium level group(greater than between 50.0 and 1000.0 U/mL)and high level group(greater than between 1000.0 U/mL).To analyze and evaluate the correlation between anti-HBV response and serum valley concentration and HBeAg level in patients treated with TDF tablets.Results:After treatment,Pearson correlation analysis showed that HBV-DNA compliance rate was positively correlated with serum valley concentration(P<0.01),but negatively correlated with HBeAg level(P;<0.05).There was no correlation with gender(P;>0.05)and age(P;>0.05).Conclusion:The anti-HBV response of TDF tablets was positively correlated with the serum valley concentration level of CHB patients.
作者
李松龙
茹仁萍
王琦
许海生
余丽霞
LI Song-long;RU Ren-ping;WANG Qi;XU Hai-sheng;YU Li-xia(Department of Pharmacy,Xixi Hospital of Hangzhou,Hangzhou 310023,China)
出处
《抗感染药学》
2021年第11期1582-1585,共4页
Anti-infection Pharmacy
基金
杭州市卫生科技计划项目(编号:2018A45)。
